Summary

US President Trump threatens tariffs up to 100 percent on medications to pressure pharmaceutical companies to relocate production to the USA. Already 17 corporations, including Novartis and Roche subsidiary Genentech, have concluded deal agreements and are exempt from tariffs for three years. Most large Swiss pharmaceutical firms are likely to come through relatively unscathed; companies without deals pay 15 percent tariffs like EU firms. Great Britain achieved a zero-tariff solution through concessions on medication prices. Switzerland is currently negotiating without price regulation as negotiating currency, but Trump signals interest in pharma-friendly pricing systems.

Persons

  • Donald Trump (US President; initiates tariff policy)
  • Dieter Bachmann (Author; NZZ business journalist)

Topics

  • Pharma tariffs and trade policy
  • Medication price regulation
  • USA-Switzerland trade negotiations
  • Production relocation

Clarus Lead

The tariff threat strategically targets two objectives: production relocation to the USA and price increases for pharmaceuticals. While large Swiss corporations are already protected, pressure intensifies on smaller firms and national regulation. The critical question mark lies not with the tariffs themselves, but whether Switzerland, like Great Britain, will be forced to liberalize its pharmaceutical pricing system – a potentially more expensive solution for the Swiss healthcare system. Trump has already announced that pharmaceutical-specific commitments should be part of trade agreements with Switzerland.

Detailed Summary

Trump announced the tariff threat immediately before Easter. It is directed against all pharmaceutical corporations that have not yet concluded a deal. Seventeen companies have already signed separate agreements that protect them from tariffs for three years; the condition is sometimes a commitment not to introduce new medications at higher prices than in other industrialized countries. Novartis and Genentech (Roche subsidiary) are among the protected firms.

For Swiss providers without a deal, a tariff rate of 15 percent applies – identical to EU firms without agreements. Sandoz, the former generics division of Novartis, benefits from lower prices and is not under scrutiny for price extremism. The small company Basilea is not considered at risk by analysts at Zurich Cantonal Bank, as its antibiotics and anti-fungal medications are health policy significant and receive state US funding.

The British model demonstrates Trump's endgame: Great Britain achieved a zero-tariff solution through price concessions – in the future, the national NHS healthcare system must accept higher pharmaceutical costs. Trump justifies this with a "fairer distribution" of development costs. Swiss associations Interpharma and Vips now demand an "equivalent solution," but see a problem: the Swiss pricing system functions completely differently from the British one. Interpharma suggests that a "modernization" of the domestic system could create a negotiation basis.

It remains unclear whether Trump will bring the medication pricing issue into ongoing Switzerland-USA negotiations. In early April, he announced that pharmaceutical-specific commitments should be integrated into existing trade agreements with the EU, Japan, Korea, Switzerland, and Liechtenstein. The Swiss State Secretariat for Economic Affairs (Seco) assures that pharmaceutical price policy is currently not a subject of negotiation. The original deadline of end-of-March for a formal agreement was missed, but negotiations are on schedule.

Key Statements

  • Deal Protection Established: 17 pharmaceutical firms have secured tariff protection for three years; major Swiss corporations are largely protected.
  • Price Regulation as Leverage: Trump uses tariffs to open national pricing systems; Great Britain paid with NHS price increases.
  • Switzerland Under Pressure: Without a formal agreement, smaller firms face 15-percent tariffs; negotiations over pricing system could be forced.

Critical Questions

  1. Evidence: On what data basis do Zurich Cantonal Bank analysts calculate that Basilea will benefit from tariff exemptions if no official commitment exists?

  2. Conflicts of Interest: To what extent could current Swiss regulatory policy be under pressure from the pharmaceutical industry, which benefits economically from price increases?

  3. Causality: Will Trump actually demand price concessions as a tariff condition, or is he using the tariff threat primarily for production relocation? What signals exist?

  4. Feasibility: Can Switzerland adapt a "British model" without destabilizing the overall pricing system, or would compromises need to imitate the NHS path?

  5. Alternative Causality: Could tariff increases occur without price negotiations if Trump is politically forced to do so (e.g., through court rulings on Section 301)?

  6. Side Effects: If Switzerland liberalizes pharmaceutical prices, what consequences would this have for health insurance premiums and patient access?

  7. Data Quality: What criteria does Trump use for exceptions (Basilea: healthcare relevance; Sandoz: generics prices)? Are these criteria transparent or ad hoc?

  8. Negotiation Status: Seco claims pharmaceutical price policy is not part of negotiations; do Trump's April announcements contradict this statement, or are there temporal/formal distinctions?

Source Index

Primary Source: Dieter Bachmann: "Trump's New Pharma Tariffs: Most Swiss Firms Likely to Come Through Relatively Unscathed – the Big Question Mark Lies Elsewhere" – Neue Zürcher Zeitung, 09.04.2026 https://www.nzz.ch/wirtschaft/trumps-neue-pharma-zoelle-die-meisten-schweizer-firmen-duerften-glimpflich-davonkommen-das-grosse-fragezeichen-steht-woanders-ld.1932568

Supplementary Sources (linked in article):

  1. Thomas Schlittler: "The British Had to Increase Medication Prices for Their Tariff Deal with Trump: Does the Same Scenario Threaten Switzerland?" – NZZ, 17.01.2026
  2. Dominik Feldges, Dieter Bachmann: "'That Only Worked Because of the Tariff Threats': Trump Concludes Deal with Roche and Novartis and Other Pharmaceutical Corporations" – NZZ, 19.12.2025

Verification Status: ✓ 09.04.2026

This text was created with the support of an AI model. Editorial Responsibility: clarus.news | Fact-Check: 09.04.2026